Mary Caffrey
Mary Caffrey is the Executive Editor for The American Journal of Managed Care® (AJMC®). She joined AJMC® in 2013 and is the primary staff editor for Evidence-Based Oncology, the multistakeholder publication that reaches 22,000+ oncology providers, policy makers and formulary decision makers. She is also part of the team that oversees speaker recruitment and panel preparations for AJMC®'s premier annual oncology meeting, Patient-Centered Oncology Care®. For more than a decade, Mary has covered ASCO, ASH, ACC and other leading scientific meetings for AJMC readers.
Mary has a BA in communications and philosophy from Loyola University New Orleans. You can connect with Mary on LinkedIn.
Articles
First-Line Tiragolumab With Atezolizumab Plus Chemo Improves PFS, OS in Patients With ESCC
Treatment with both PD-1 and TIGIT immunotherapy alongside chemotherapy demonstrated improved progression-free (PFS) and overall survival (OS) compared with chemotherapy alone in patients with esophageal squamous cell carcinoma (ESCC).
Study Finds Huge Gap Between Clinical Trial Data and Real-World Outcomes in Multiple Myeloma
Real-world patients were on average older and had more comorbidities than those in clinical trials, factors previously seen in comparisons between patients in clinical trials and real-world settings.
Data Show Trend Toward Improved Persistence After 6 Months With Oral MDS Regimen
The authors concluded that the data support consideration of the oral regimen of decitabine and cedazuridine to reduce the treatment burden associated with intraveous or subcutaneous hypomethylating agents in patients with myelodysplastic syndromes (MDS).
Preventing Adverse Events With Bispecific Antibodies in Myeloma in the Community Setting
Robert Rifkin, MD, medical oncologist and hematologist at Rocky Mountain Cancer Centers, shares insight into how the phase 2 Optec study of teclistamab administration in the outpatient setting could help achieve important health equity and quality goals.
Pivotal Results Show Revumenib Holds Promise for Patients With KMT2Ar Acute Leukemia
In AUGMENT-101, patients with R/R KMT2Ar acute leukemia had high overall response rates; despite being heavily pretreated, 40% were able to proceed to transplant and the KMT2Ar cohort was stopped early.
BOVen: Zanubrutinib, Obinutuzumab, and Venetoclax Yields 75% OS at 2 Years in High-Risk MCL
In a packed session Monday at the 65th American Society of Hematology Annual Meeting and Exposition in San Diego, California, Anita Kumar, MD, of Memorial Sloan Kettering Cancer Center, presented phase 2 results for 25 patients with TP53 mutations.
Results Show Strong Responses for Brentuximab Vedotin Plus Nivolumab Combo in Patients With cHL
Use of an antibody drug conjugate and a PD-1 inhibitor brings complementary mechanisms together while eliminating the most toxic agent that has been used in combinations to treat classic Hodgkin lymphoma (cHL).
Dr Jennifer Brown: Zanubrutinib Efficacy Holds Up at ALPINE 39-Month Follow-Up in R/R CLL
Jennifer R. Brown, MD, PhD, director of the Chronic Lymphocytic Leukemia (CLL) Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute, discussed the updated findings from the phase 3 ALPINE trial of zanubrutinib vs ibrutinib in relapsed/refractory CLL (R/R CLL) at 39 months of follow-up.
